Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Clinical trial NCT05430217 · COMPLETED

Trial details

NCT number: NCT05430217
Sponsor: Valenta Pharm JSC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Vertigo Autonomic Dysfunction

Start date: 2022-01-28
Primary completion: 2022-05-09
Enrollment: 268

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.